John Macor earned his BS degree from the University of Notre Dame in 1982 doing undergraduate research with Professor Marvin Miller and earned his PhD degree at Princeton University with Professor E. C. Taylor in 1986. John has 35 years pharmaceutical/drug discovery experience having worked for Pfizer, Astra, BMS, and is presently the Global Head of Integrated Drug Discovery for Sanofi with groups in Paris, Frankfurt and Waltham, MA.
John is a co-inventor of Relpax® (eletriptan), an anti-migraine agent (5HT1D receptor agonist) discovered during his time at Pfizer. At BMS, he was also a co-inventor of Nurtec ODT® (rimegepant), a CGRP receptor antagonist for the treatment of migraine. Dr. Macor is also a co-inventor of many other compounds that progressed into clinical trials, including LX9211 (an AAK1 inhibitor for neuropathic pain, Phase 2) and zavegepant (intranasal CGRP antagonist for migraine, Phase 3).
John has more than 500 peer-reviewed publications, issued US patents, meeting presentations and invited lectures. Dr Macor served as Editor-in-Chief of Annual Reports in Medicinal Chemistry for Volumes 42 – 46 (2006 – 2011) and was Chair of MEDI in 2015. John has been awarded the 2009 Scarborough Award in Medicinal Chemistry, the 2014 Alfred Burger Award in Medicinal Chemistry, the 2019 Smissman Award, and the 2020 IUPAC-Richter Prize. He is an ACS Fellow (2011) and is an inductee in the MEDI Hall of Fame (2014, see: https://www.acsmedchem.org/?nd=Macor).